Business
Correction: Director Share Purchases
Correction: Director Share Purchases.
About this update from Theracryf Plc
[{"type":"text","content":"\n \nRNS Number : 3512M Evgen Pharma PLC 19 January 2016 \n\nFor immediate release 19 January 2016\n \n \nThe Evgen Pharma plc Director Share Purchases announcement released on 19 January 2016 at 7.00am under RNS No 2412M incorrectly stated that the price paid per share was 22.5p. This should have read 22.25p per share. All other details remain unchanged. The full amended text is shown below.\n \n \n \nEvgen Pharma plc\n \n(\"Evgen\" or the \"Company\")\n \nDirector Share Purchases\nEvgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that, on 18 January 2016, certain Directors purchased an aggregate of 136,000 ordinary shares of 0.25 pence each at a price of 22.25 pence per share. The Directors participating in the purchase and their interests in the share capital of the Company following the purchase are as follows:\n\n\n\n\nDirector\n\n\nNumber of Ordinary Shares pursuant to Directors' dealing\n\n\nHolding following Directors' dealing \n\n\nPercentage of Ordinary Shares following Directors' dealing\n\n\n\n\n \n\n\n \n\n\n \n\n\n \n\n\n\n\nBarry Clare\n\n\n40,000\n\n\n940,108\n\n\n1.3%\n\n\n\n\nStephen Franklin\n\n\n56,000\n\n\n1,375,200\n\n\n1.9%\n\n\n\n\nJohn Bradshaw\n\n\n40,000\n\n\n40,000\n\n\n0.1%\n\n\n\n\n \n \nEnquiries:\n\n\n\n\nEvgen Pharma plc\n\n\n+44 (0) 20 7466 5000\n\n\n\n\nDr Stephen Franklin, CEO\n\n\n \n\n\n\n\nwww.evgen.com \n\n\n \n\n\n\n\n \n\n\n \n\n\n\n\nNorthland Capital Partners Limited\n\n\n+44 (0) 20 7382 1100\n\n\n\n\nMatthew Johnson, Gerry ...